These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 33786987)
1. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis. Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987 [TBL] [Abstract][Full Text] [Related]
2. The transmembrane protein LRIG2 increases tumor progression in skin carcinogenesis. Hoesl C; Fröhlich T; Hundt JE; Kneitz H; Goebeler M; Wolf R; Schneider MR; Dahlhoff M Mol Oncol; 2019 Nov; 13(11):2476-2492. PubMed ID: 31580518 [TBL] [Abstract][Full Text] [Related]
3. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598 [TBL] [Abstract][Full Text] [Related]
4. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710 [TBL] [Abstract][Full Text] [Related]
5. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Billing O; Holmgren Y; Nosek D; Hedman H; Hemmingsson O Oncogene; 2021 May; 40(21):3707-3718. PubMed ID: 33947959 [TBL] [Abstract][Full Text] [Related]
7. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma. Liu S; Geng R; Lin E; Zhao P; Chen Y Front Genet; 2021; 12():602160. PubMed ID: 33732282 [TBL] [Abstract][Full Text] [Related]
8. Aryl Hydrocarbon Receptor Defect Attenuates Mitogen-Activated Signaling through Leucine-Rich Repeats and Immunoglobulin-like Domains 1 (LRIG1)-Dependent EGFR Degradation. Hsu HL; Chen HK; Tsai CH; Liao PL; Chan YJ; Lee YC; Lee CC; Li CH Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576152 [TBL] [Abstract][Full Text] [Related]
9. ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis. Dahlhoff M; Schäfer M; Muzumdar S; Rose C; Schneider MR Mol Oncol; 2015 Nov; 9(9):1825-33. PubMed ID: 26194695 [TBL] [Abstract][Full Text] [Related]
10. Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. Xian W; Rosenberg MP; DiGiovanni J Oncogene; 1997 Mar; 14(12):1435-44. PubMed ID: 9136987 [TBL] [Abstract][Full Text] [Related]
11. LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition. Li W; Zhou Y Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30487162 [TBL] [Abstract][Full Text] [Related]
12. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Yi W; Holmlund C; Nilsson J; Inui S; Lei T; Itami S; Henriksson R; Hedman H Exp Cell Res; 2011 Feb; 317(4):504-12. PubMed ID: 21087604 [TBL] [Abstract][Full Text] [Related]
13. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. Lu L; Teixeira VH; Yuan Z; Graham TA; Endesfelder D; Kolluri K; Al-Juffali N; Hamilton N; Nicholson AG; Falzon M; Kschischo M; Swanton C; Wright NA; Carroll B; Watt FM; George JP; Jensen KB; Giangreco A; Janes SM J Pathol; 2013 Mar; 229(4):608-20. PubMed ID: 23208928 [TBL] [Abstract][Full Text] [Related]
14. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323 [TBL] [Abstract][Full Text] [Related]
15. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study. Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114 [TBL] [Abstract][Full Text] [Related]
16. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis. Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341 [TBL] [Abstract][Full Text] [Related]
17. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Miller JK; Shattuck DL; Ingalla EQ; Yen L; Borowsky AD; Young LJ; Cardiff RD; Carraway KL; Sweeney C Cancer Res; 2008 Oct; 68(20):8286-94. PubMed ID: 18922900 [TBL] [Abstract][Full Text] [Related]
18. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116 [TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is downregulated in Invasive ductal carcinoma and potential prognostic marker of breast cancer. Piracha ZZ; Saeed U J Cancer Res Ther; 2023 Oct; 19(7):1870-1879. PubMed ID: 38376291 [TBL] [Abstract][Full Text] [Related]
20. The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation. Hoesl C; Röhrl JM; Schneider MR; Dahlhoff M Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):958-966. PubMed ID: 29410073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]